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Abstract
Background—According to the American Psychiatric Association Clinical Practice Guidelines 
for schizophrenia, second-generation antipsychotics may be specifically indicated for the 
treatment of depression in schizophrenia. We examined the impact of these medications on 
symptoms of depression using the data from the Clinical Antipsychotic Trials of Intervention 
Effectiveness (CATIE), conducted between January 2001 and December 2004.
Method—Patients with DSM-IV–defined schizophrenia (N = 1,460) were assigned to treatment 
with a first-generation antipsychotic (perphenazine) or one of 4 second-generation drugs 
(olanzapine, quetiapine, risperidone, or ziprasidone) and followed for up to 18 months (phase 1). 
Patients with tardive dyskinesia were excluded from the randomization that included 
perphenazine. Depression was assessed with the Calgary Depression Scale for Schizophrenia 
(CDSS). Mixed models were used to evaluate group differences during treatment with the initially 
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assigned drug. An interaction analysis evaluated differences in drug response by whether patients 
had a baseline score on the CDSS of ≥ 6, indicative of a current major depressive episode (MDE).
Results—There were no significant differences between treatment groups on phase 1 analysis, 
although there was a significant improvement in depression across all treatments. A significant 
interaction was found between treatment and experiencing an MDE at baseline (P = .05), and 
further paired comparisons suggested that quetiapine was superior to risperidone among patients 
who were in an MDE at baseline (P = .0056).
Conclusions—We found no differences between any second-generation antipsychotic and the 
first-generation antipsychotic perphenazine and no support for clinical practice recommendations, 
but we did detect a signal indicating a small potential difference favoring quetiapine over 
risperidone only in patients with an MDE at baseline.
Since their introduction in the 1990s, second-generation antipsychotics (SGAs) have become 
the drugs of choice in the treatment of schizophrenia, despite a lack of conclusive evidence 
of superior efficacy as assessed by measures of general psychopathology.1–5 One meta-
analysis has, however, suggested that not all SGAs are equivalent.6
Depression is a common symptom over the course of schizophrenia.7,8 It is a predictor of 
attempted suicide and suicide9,10 and is an important determinant of quality of life.11 When 
depressive symptoms meet the syndromal criteria for major depressive disorder, 
antidepressants have been suggested as adjunctive treatment to antipsychotics.12
Early suggestions that first-generation antipsychotics (FGAs) might have antidepressant 
properties notwithstanding,13 depression has been identified as a potential treatment target 
for which SGAs were suggested to have a differential effect in comparison to FGAs.14–17 
The American Psychiatric Association Clinical Practice Guidelines assigned a level II 
evidence for a recommendation on the use of SGAs for the treatment of depression in 
schizophrenia not associated with relapse.12 While some studies suggest a specific 
antidepressant effect for SGAs, and for olanzapine in particular, mediated through 1 or more 
non-D2 pathways,15 others have suggested that the difference detected in some studies may 
have reflected akinesia due to a lack of prophylactic anticholinergic medication in the FGA 
arm of the studies involving moderate to high doses of the high-potency drug haloperidol.18 
It has also been suggested that in drug-naive patients, depression in schizophrenia is related 
to low presynaptic dopamine function.19 In contrast to trials that have not consistently 
demonstrated clinical superiority of SGAs over FGAs, clozapine has more consistently been 
more effective than other antipsychotics including SGAs in the treatment of refractory 
schizophrenia.20,21 More specifically, in the treatment of symptoms of depression, clozapine 
has been shown to be more effective than risperidone in reducing symptoms of depression in 
a study of people with treatment-resistant schizophrenia.22 Thus, the only antipsychotic that 
has consistently shown evidence of superior efficacy in terms of the positive symptoms of 
schizophrenia has also shown increased effectiveness against symptoms of depression.
The published reports on the treatment of depression in schizophrenia with antipsychotics 
usually examine depression as a secondary outcome measure. A recent meta-analysis of 
SGAs for people with both schizophrenia and depression included only 3 methodologically 
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rigorous studies for which depression was the primary outcome.23 The conclusion of this 
review was that there were insufficient data to guide patients, prescribers, caregivers, or 
policy makers and that further studies were warranted.
In 1999, the National Institute of Mental Health initiated the Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE), which used an experimental study design to compare 
the effectiveness of 1 FGA (perphenazine) and all 4 SGAs (olanzapine, risperidone, 
quetiapine, and ziprasidone) other than clozapine, that were available in the United States in 
January 2002 for the treatment of chronic schizophrenia. A report on the primary clinical 
outcomes from CATIE, considering only treatment on the initial randomly assigned drug 
(phase 1), found that patients treated with olanzapine remained on treatment with their 
medicine longer than those treated with quetiapine or risperidone and were less likely than 
all of those receiving other drugs to switch drugs for lack of efficacy.5 None of the second-
generation drugs showed statistically significantly greater efficacy or tolerability than the 
first-generation drug, perphenazine, nor were there any significant differences on measures 
of neurologic side effects. Weight gain with olanzapine was substantial, averaging 2 lb per 
month, with concomitant increases in hemoglobin A1c, cholesterol, and triglycerides.
The clinical outcome assessments used in the CATIE study were selected to represent all 
symptoms and outcomes of relevance to clinical practice, including depression.24 In this 
study, we examine the differential impact of 4 second- generation drugs and perphenazine on 
symptoms of depression in the overall CATIE study sample and evaluate whether there are 
differences in drug effects in the subsample who met criteria for a major depressive episode 
(MDE) on the primary measure of depressive symptoms (Calgary Depression Scale for 
Schizophrenia [CDSS]).
METHOD
Study Setting and Design
CATIE was conducted between January 2001 and December 2004 at 57 US sites and 
included an algorithmically determined series of treatment phases. Patients were initially 
assigned to olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone under double-
blind conditions. However, patients with tardive dyskinesia (TD) (15% of the sample) were 
not considered in the randomization that included perphenazine and thus were not available 
for comparisons involving that drug. Although not reported here, patients who discontinued 
their first treatment were invited to further random assignment to other SGAs, including 
clozapine, if they so desired. Open treatment was also offered to patients who refused a 
second blind assignment or whose treatment failed after a second assignment (phase 3), 
when a small number chose FGAs.
Participants
The study was approved by an institutional review board at each site. Patients 18 to 65 years 
of age with a diagnosis of schizophrenia25 who were able to take oral antipsychotic 
medication were eligible. Patients or their guardians provided written informed consent. 
Patients were excluded if they had a diagnosis of schizoaffective disorder or mental 
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retardation or other cognitive disorders, an unstable serious medical condition, past adverse 
reactions to a proposed treatment, or treatment-resistant schizophrenia or if they were in 
their first episode of schizophrenia, pregnant, or breastfeeding.
Interventions
Identical capsules contained olanzapine (7.5 mg), quetiapine (200 mg), risperidone (1.5 mg), 
perphenazine (8 mg), or ziprasidone (40 mg). Ziprasidone was approved for use by the US 
Food and Drug Administration during the trial and was added in January 2002, after 40% of 
the sample had been recruited. Medications were flexibly dosed with 1 to 4 capsules daily, 
as judged by the study doctor. Concomitant medications were permitted, except for 
additional antipsychotic agents. Further details about blinding, later phases of treatment, and 
modal dosing have been presented elsewhere.5,26
Measures
A full description of the measures used in this study is reported elsewhere.24 The outcome of 
primary interest for this analysis is depression, which was assessed with the CDSS.27 The 
CDSS is a measure of depression specifically designed to assess depression in schizophrenia 
separate from negative symptoms.28 It has been validated in independent studies29,30 and 
recommended as the gold standard for assessing depression in schizophrenia for clinical 
trials.31
For the purpose of this analysis, patients with a baseline score of ≥ 6 on the CDSS were 
identified as meeting CDSS criteria for an MDE and thus most likely to benefit from 
treatment. This level of depression has been previously identified as an appropriate cutoff for 
the prediction of a major depressive disorder, with a specificity of 77% and sensitivity of 
92%.32
Statistical Methods
For consistency and comparability, the statistical methods used in the analysis of continuous 
measures in this study were the same as those used in the original publication from CATIE.5 
The main analyses are limited to the period of treatment with the initially assigned drug 
(phase 1). The central analysis was a paired comparison between treatment groups of 
average CDSS scores from all timepoints using a mixed model including terms representing 
treatment group, the baseline value of the CDSS, time (treated as a classification variable for 
months 1, 3, 6, 9, 12, 15, and 18), site, a history of recent clinical exacerbation, and 
baseline-by-time interactions. The baseline-by-time term adjusts for baseline differences in 
characteristics of patients who dropped out early and thus are less well represented at later 
timepoints. Treatment-by-time interactions to evaluate differences in time trends between 
groups were also tested. A random subject effect and a first-order autoregressive covariance 
structure were used to adjust standard errors for the correlation of observations from the 
same individual.
Two hundred thirty-one patients with TD were ex cluded from assignment to perphenazine, 
and ziprasidone was added to the trial after 40% of the patients had been enrolled. 
Randomization occurred under 4 separate regimens: including and excluding patients with 
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TD, and including and excluding ziprasidone. Analyses were thus con ducted on 4 different 
datasets with overlapping membership. Each dataset included only patients with an equal 
chance of being randomly assigned to the treatments under comparison. Perphenazine-
treated patients, in particular, were compared only to equivalent patients who did not have 
TD at baseline.
The primary comparison between the 4 treatments available at the beginning of the trial was 
an overall 3 degree of freedom test. This test was performed on analytic dataset 1, excluding 
both patients with TD and those randomly assigned to ziprasidone. If the overall test was 
significant at P < .05, the 3 second-generation drugs were compared with perphenazine with 
a Hochberg adjustment for multiple comparisons33 in which the smallest P value was 
compared to .05/3 = .017 and the largest to P = .05.
Next, with the use of dataset 2, which excludes perphenazine and includes TD patients, the 3 
second-generation drugs were compared to each other via step-down testing. If the overall 2 
degree of freedom test was significant at P < .05, an α of P < .05 was applied for all 
comparisons.
Datasets 3 and 4 were used to compare ziprasidone to the other 4 drugs among patients 
randomized after ziprasidone became available, but with TD patients excluded from the 
perphenazine comparison. Hochberg adjustment for 4 pairwise comparisons was used to 
compare ziprasidone and perphenazine in dataset 3 and ziprasidone to the other 3 drugs in 
dataset 4. The smallest P value was considered significant if P = .05/4 = .013.
Because the impact of these medications on depressive symptoms may have been different 
among patients who met criteria for an MDE at the time of study entry than among patients 
who did not, a set of interaction analyses was conducted within each of the 4 strata. Within 
each stratum, an interaction term was modeled representing the interaction of treatment 
group by a dichotomous variable indicating whether the patient had met criteria for 
depression using 2 criteria: a categorical criterion of a major depressive disorder using the 
CDSS cutoff score of ≤ 6 or greater at baseline and a continuous criterion level of depression 
assessed on the CDSS. These analyses allowed us to determine whether there were 
differences between treatment effects among patients who met these a priori criteria for 
depression and patients who did not. If the interaction term was significant, paired 
comparisons between treatments were conducted among patients who met the criterion for 
depression and among patients who did not. Because these analyses were descriptive in 
nature, an α level of P < .05 was used to test paired comparisons.
RESULTS
Characteristics and Disposition
The baseline demographic and clinical characteristics of the patients have been described in 
a previous publication and showed no significant differences between treatment groups on 
baseline measures.5 Although 1,493 patients were enrolled in the study, all data from 1 site 
(33 patients) were excluded prior to analysis due to concerns about data integrity, and 17 
patients never took study drug. A total of 448 (30.69%) patients had a CDSS score of ≤ 6 at 
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baseline and were considered to be in a current MDE. Patients with an MDE were more 
often white (P = .04), female (P = .006), and younger (P = .02) and had fewer years of 
treatment (P = .02).
The total CDSS score improved over time in all groups (Figure 1). The mixed models, 
however, revealed no overall significant differences between treatments within any of the 4 
strata (Table 1). There were also no significant treatment-by-time interactions indicating 
differences in rates of change in depressive symptoms.
Interaction analyses of treatment group by MDE at baseline showed interactions between the 
presence of major depressive disorder at baseline and treatment group in 2 of the analytic 
strata. The first interaction was observed in dataset 1, the stratum that included patients 
without TD assigned perphenazine, olanzapine, quetiapine, or risperidone (P < .02), but 
examination of paired comparisons showed no significant differences involving 
perphenazine.
An interaction was also observed in dataset 2, the stratum that included all patients randomly 
assigned to olanzapine, risperidone, or quetiapine (P = .05). Further paired comparisons of 
CDSS scores among patients meeting criteria for MDE showed a small but statistically 
significant difference between quetiapine and risperidone (mean = 8.52 for quetiapine vs 
9.06 for risperidone, P = .0056), indicating that patients receiving quetiapine had lower 
depression scores than those receiving risperidone, specifically among patients who met 
criteria for MDE (Figure 2). Further examination of paired differences between these drugs 
at specific time-points showed that lower depression scores with quetiapine were observed at 
only 4 of 7 timepoints: months 3, 6, 9, and 18 (Figure 2).
DISCUSSION
The main finding of this study is that we found no evidence of a class benefit of the use of 
SGAs compared with FGAs in the treatment of symptoms of depression, even in the subset 
that was above the baseline threshold for MDD. Depression was not the primary outcome 
measure for this study, and the sample size was not powered for this outcome. Thus, these 
analyses should be considered descriptive.
Despite this, our post hoc assessment of the results suggests that the clinical importance of 
the results would not be different if the sample had been larger. The standard deviation for 
depression scores was 5.0, and the few differences favoring SGAs are all less than 0.1 
(0.026–0.04), resulting in effect sizes of less than 0.01. An effect size of 0.2 is considered 
small, and anything less than 0.2 is not likely to be of clinical importance.
However, in a subsample of schizophrenia patients identified as meeting criteria for MDE, 
those assigned to quetiapine had lower scores than those assigned to risperidone, but, again, 
no FGA-SGA differences were seen. These results are in contrast to studies that have 
reported a difference in change in depression between SGAs and haloperidol.15–17 
Furthermore, the findings do not lend empirical support to the recommendation for SGAs in 
schizophrenia with depression of the American Psychiatric Association Clinical Practice 
Guidelines, a level II recommendation meaning “Recommended with moderate clinical 
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confidence.”12 It has been suggested that the findings of reduced changes in depression with 
haloperidol as compared to SGAs may have been due to akinetic extrapyramidal side effects 
(EPS) in the absence of prophylactic anticholinergics.18 The CATIE results presented here, 
in contrast to earlier studies, used an intermediate-potency FGA, perphenazine, and found no 
significant differences among groups in the incidence of extrapyramidal side effects, 
akathisia, or movement disorders or in the prescription of concomitant anticholinergic or 
antidepressant medications.5 Although there were no overall differences in frequency of 
antidepressant prescription between antipsychotics in the original CATIE report,5 the rate of 
prescription was highest in the risperidone group, 16%, and lowest in the quetiapine group, 
8%, with perphenazine between these 2 SGAs, at 11%. Although the exact timing and 
duration of antidepressant treatment are not known, the results favoring quetiapine over 
risperidone are not likely to be an artifact of greater use of concomitant antidepressant 
treatment in the quetiapine group.
Another possible explanation of the differences in findings between this study and earlier 
studies is that both of the earlier studies found differences in change in positive and negative 
symptoms of schizophrenia or global psychopathology, as assessed by the Positive and 
Negative Syndrome Scale (PANSS), between SGAs and haloperidol. In contrast to those 
other studies, there were no differences in change in global psychopathology in the CATIE 
study. In studies of treatment response to antipsychotic medications, there is evidence that 
depressive symptoms in acute schizophrenia improve in conjunction with changes in global 
psychopathology.34 Although the CATIE study was not an acute treatment study, there were 
statistically significant changes in global psychopathology over time. If the primary driver of 
reductions in depression is improvement in global psychopathology, then one would expect 
that treatments of equivalent efficacy in the treatment of general psychopathology would 
have equivalent effects on depression in schizophrenia. Such a general principle would 
explain the finding in studies comparing clozapine to other antipsychotics in treatment-
resistant schizophrenia in which differential improvements in depression coincided with 
differential improvements in general psychopathology favoring clozapine.22
Despite the finding of no general effect for SGAs, this study did find evidence of a 
statistically significant difference between quetiapine and risperidone. While the size of the 
difference is clinically small, these results are congruent with a study comparing quetiapine 
with haloperidol in partially responsive schizophrenia35 that showed a differential effect of 
quetiapine on the PANSS depression factor compared with haloperidol despite no difference 
in change in global psychopathology between treatments. Positron emission tomography 
studies in humans suggest that risperidone and quetiapine are at opposite ends of the range 
of dopamine affinity.36,37 The low and transient D2 occupancy of quetiapine appears to 
account for its low potential for EPS. This would fit the theory that depression may be 
exacerbated either by EPS or by the high dopamine blockade that underlies EPS. In contrast 
to quetiapine, risperidone has the highest D2 receptor affinity of the drugs used in this study, 
comparable to that of haloperidol.38 It would also fit with a theory that the mesolimbic 
dopamine reward circuit plays a part in depression39 and that higher occupancy of dopamine 
D2 receptors may be associated with increased feelings of dysphoria.40,41 The same theory 
might also explain the earlier findings of reduced depression in studies comparing SGAs 
versus relatively high doses of haloperidol, but these pharmacologic conceptualizations 
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remain speculative. An alternative explanation might be that a metabolite of quetia-pine, N-
desalkylquetiapine, has antidepressant properties.42
Strengths of the study were its large sample size, long duration of follow-up, and recruitment 
of patients from diverse representative sites with minimal exclusion criteria—all of which 
increase the generalizability of the results. The investigators also selected a depression scale 
that was specifically designed for the assessment of depression in schizophrenia and that 
avoids the confounds of negative symptoms, extrapyramidal symptoms, and depression.
Limitations of this study include the use of secondary outcome data and data loss from 
attrition. While patients treated with olanzapine stayed significantly longer on treatment than 
risperidone or quetiapine, there were no differences in duration of treatment between 
patients treated with quetiapine and risperidone.
In contrast to some previous research and a level II APA guideline, this study of the impact 
of antipsychotics on depressive symptoms in patients with schizophrenia found no 
differences between any SGA, including olanzapine, and the FGA perphenazine, but we did 
detect a signal indicating a small difference favoring quetiapine over risperidone that was 
limited to patients with an MDE at baseline.
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